NCT05957640

Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma

Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma: A Multicentre, Prospective, Open-label, Single-arm Trial

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Zhongda Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma

Detailed description

The efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma remain unknown. This multicentre, prospective, open-label, single-arm trial is designed to evaluate the safety and efficacy of yttrium-90 carbon microspheres in patients with hepatocellular carcinoma. The primary endpoints are safety and local objective response rate of liver target lesions. While the secondary endpoints include the time to progression, progression-free survival rates, disease control rates, duration of response, quality of life and the distribution characteristics of yttrium-90 carbon microspheres.

Conditions

• Unresectable Hepatocellular Carcinoma

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Yttrium-90 carbon microspheres SIRT	Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres

Timeline

• Start date: 2023-05-05
• Primary completion: 2025-05-31
• Completion: 2025-05-31
• First posted: 2023-07-24
• Last updated: 2023-07-24

Locations

1 site across 1 country: China